Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Valeant Pharma (VRX) Setting Stage for Potential Capital Raise in 2018 - Evercore ISI's Raffat
February 28, 2018 9:50 AM ESTEvercore ISI analyst Umer Raffatt thinks Valeant Pharma (NYSE: VRX) could tap the capital market this year.
He notes while Valeant gave no clear answer on whether Valeant will look to raise capital near term and emphasized that there... More
Valeant Pharma (VRX) Posts Mixed Q4
February 28, 2018 7:05 AM ESTValeant Pharma (NYSE: VRX) reported Q4 GAAP EPS of $1.45, which may not compare to the analyst estimate of $0.97. Revenue for the quarter came in at $2.16 billion versus the consensus estimate of $2.18 billion.
Adjusted EBITDA (non-GAAP) was $875 million for the fourth quarter of 2017, as... More
